Addition Of Everolimus To Exemestine Provides Sustained Survival Edge In Women With Advanced Breast Cancer

SAN ANTONIO - The survival benefit seen with everolimus plus exemestane over exemestane alone at 7.5 months and 12.5 months in women with advanced breast cancer is maintained at 18- month follow-up, investigators announced at the San Antonio Breast Cancer Symposium (SABCS)...



Cancer-Medicine in USA